Bethesda Diabetes Center, Hoogeveen Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
1998
NCT00375388
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1998

Timeline

NOW
  • Now

Alternative names

Bethesda General Hospital and Bethesda Diabetes Center, Hoogeveen, The Netherlands (for address: see above)

Active Ingredients

Drugs in Phase 3 Trials (1)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1